ScienceIn Publishing

Author: The ScienceIN

  • Dr. S. Balakumar

    Dr. S. Balakumar
    National Centre for Nanoscience and Nanotechnology
    University of Madras Maraimalai (Guindy) Campus
    Chennai-600025

    Dr. Balakumar is the director of National Centre for Nanoscience and Nanotechnology, Madras University. He has several awards and patents to his credit such as IME Team Excellence Award on Nanowires project, 2008
    IME Long Term Service award, 2007
    IEEE Senior Membership Award, 2004
    JSPS Fellowship, Japan 2000
    STA Fellowship, 2001
    NSTB Fellowship by Singapore A-Star -1997-1999
    CUHK University fellowship (1995-97)
    CSIR Research Fellowship to carry out Ph.D, 1994
    CSIR Travel Award to attend IMf1993, USA
    DST Full Travel Award to attend and Chair MRS 2009
    US Patents : High Speed Nanowire Semiconductor Devices based on Hetero structure and formation of Such ( Patent filed, 2007)
    U.S. Patent:High K artificial lattices for capacitor applications to use in CU or AL BEOL, Patent No. 6,830,971
    U.S. Patent Linear polishing for improving substrate uniformity, U. S Patent: 6,726,545, April 27, 2004
    U.S. Patent: Multiple steps CMP polishing, U. S Patent: 6,663,472, December 16, 2003
    U.S. Patent: Method to form shallow trench isolations, U.S. Patent: 6,649,486 , November 18, 2003
    U.S. Patent: Method for improving oxide erosion of tungsten CMP operations, U. S. Patent: 6,569,770,, May 27, 2003
    U.S. Patent: CMP uniformity, U.S. Patent: 6,248,006 June 19, 2001.

    His research interests are Multifunctional Nanomaterials, Multiferroics nanomaterials, Metal Oxide Nanostructures for sensor and Photocatalytic application, Micro/Nanoelectronic Fabrication Processes, Cu-interconnects, Chemical Mechanical Planarization and Clean technology, Nanobioglasses for medical applications.

    Dr. Balakumar is associated with ‘Journal of Materials NanoScience‘ as Editorial Advisory Board Member.

  • Nuclear Medicine advances in development of radiopharmaceuticals for Scintigraphy, Positron Emission Tomography and Radiotherapy

    Guest Editorial for special issue on Nuclear Medicine

    Source:: http://www.pubs.iscience.in/journal/index.php/cbl/article/view/767

          

  • Dr Sumit Kumar Malik

    Dr Sumit Kumar
    Department of Chemistry,
    DCR University of Science and Technology (DCRUSTM)
    Murthal, Sonepat, Haryana, India.

    Research Interests: Hydrogel, Dendrimers, Nano Drug Delivery, Organic and Bioorganic Chemistry.

    Dr. S. Kumar is associated with ‘Chemical Biology Letters‘ as editorial advisory board member.

    Chemical Biology Letters
    Chemical Biology Letter – View Journal site

  • Radiopharmaceuticals for diagnosis of Primary Hyperparathyroidism

    Hyperparathyroidism (HPTH) is a condition in which the level of parathyroid hormone in blood is raised. Gold standard for the diagnosis of HPTH is a measurement of serum parathyroid hormone levels, accompanied by testing serum calcium levels, to differentiate between primary and secondary HPTH. The first line of treatment with primary HPTH is surgery to remove the adenoma or the tumor, whenever possible. It is in these cases that the imaging plays an important role for localization of tumor before surgery.Imaging can be anatomical that is ultrasound, CT and MRI or functional that is using nuclear medicine modalities (SPECT, SPECT/CT, PET/CT). This article reviews the nuclear medicine modalities, various radiopharmaceuticals and imaging techniques for parathyroid imaging.

    Source:: http://www.pubs.iscience.in/journal/index.php/cbl/article/view/726

          

  • Radiolabelled nanoparticles in cancer treatment: current status and developments

    The current concepts of cancer therapy are moving towards personalized treatment regimen aiming to reduce toxicity and improve efficacy of therapeutic agents. With the development of molecular imaging and targeted therapies personalized care has received a shot in the arm. However, these developments are not without challenges. Drug delivery, metabolism, toxicity etc. challenge the effective utilization of such agents. Nanoparticles offer to overcome these hurdles with their unique physico-chemical properties which can be labeled with radionuclides and conjugated with ligands to achieve high specific activity in the intended areas. In this article, we discuss the present status of radiolabeled nanoparticles, the areas where they are being used and challenges that lie ahead. We intend to provide a basic outlook on the utilization of radiolabeled nanoparticles in cancer diagnosis and therapy.

    Source:: http://www.pubs.iscience.in/journal/index.php/cbl/article/view/728

          

  • Prof. Santanu Bhattacharya | Materials NanoScience Editorial Advisory Board Member

    Professor S. Bhattacharya did Ph.D. from Rutgers University, New Brunswick, NJ, USA (Advisor: Prof. Robert. A. Moss) in 1988. From 1988 to 1991 he worked as Postdoctoral Research Associate at the Massachusetts Institute of Technology, Cambridge, MA, USA (Prof. Har Gobind Khorana, Nobel Laureate) and in 1991 he joined as Assistant Professor in Organic Chemistry division, Indian Institute of Science, Bangalore, India where he was promoted as Professor in 2001. He served as Chairman of department of Organic Chemistry, Indian Institute of Science from 2012 to 2015 and since April 22, 2015 he is Director and Senior Professor, Director’s Research Unit, Indian Association for the Cultivation of Science (IACS), Kolkata. India.

    He has received numerous excellence awards such as
    Ranbaxy Research Award, Pharmaceutical Sci., Ranbaxy Science Foundation 2013
    Elected Fellow of the World Academy of Sciences 2012
    TWAS Prize, The World Academy of Sciences, Trieste, Italy 2010
    J. C. Bose National Fellowship, Department of Science & Technlogy 2008
    Elected Fellow of Indian National Science Academy 2007
    G.D. Birla Prize for Scientific Research, K.K. Birla Foundation 2007
    Shanti Swarup Bhatnagar prize for the Chemical Sciences, CSIR 2003
    National Bioscience Career Development Award, Department of Biotechnlogy 2002
    Elected Fellow of Indian Academy of Sciences 2000
    Swarnajayanti Fellowship, Department of Science & Technlogy 1998

    He is associated with ‘Journal of Materials NanoScience‘ as Editorial Advisory Board Member since 2014. The journal link is http://www.pubs.iscience.in/journal/index.php/jmns

  • Synthesis and Evaluation of [DUPA-6-Ahx-Lys (DOTA)-6-Ahx-RM2], a Novel, Bivalent Targeting Ligand for GRPr/PSMA Biomarkers of Prostate Cancer

    In this study, we have prepared a novel, dual-biomarker, targeting ligand having high affinity and specificity for PSMA/GRPr receptors that are expressed on most prostate cancers. [DUPA-6-Ahx-Lys(DOTA)-6-Ahx-RM2] was synthesized and the new conjugate was metallated macroscopically with GaCl3, InCl3, and LuCl3 to form [DUPA-6-Ahx-Lys(M-DOTA)-6-Ahx-RM2] (where M = Ga, In, or Lu). These new agents, when radiolabeled with Ga-68, In-111, or Lu-177 hold theranostic potential for patients presenting with prostate cancer disease.

    Source:: http://www.pubs.iscience.in/journal/index.php/cbl/article/view/718

          

  • Synthesis and evaluation of a novel 68Ga-NODAGA-Erlotinib analogue towards PET imaging of Epidermal Growth Factor Receptor over-expressing cancers

    In this paper we report the synthesis of 68Ga labeled NODAGA-Erlotinib for imaging of EGFR over-expressing tumors. NODAGA-Erlotinib conjugate was synthesized by reaction of the terminal alkyne of Erlotinib using Cu catalyzed click reaction. The conjugate was then radiolabeled with 68Ga in high radiochemical yields. The 68Ga NODAGA-Erlotinib conjugate also exhibited high in vitro stability. The log P value of 68Ga-NODAGA-Erlotinib was lower than that of 68Ga-NOTA-Erlotinib, a 68Ga based Erlotinib conjugate previously reported by our group. In the in vitro cell binding studies carried out in EGFR-positive A431 cells, 68Ga-NODAGA-erlotinib exhibited an uptake (7.8±1.3 %) lower than that of 68Ga-NOTA-Erlotinib (9.8±0.4%) showing that an increase in hydrophilicity possibly effected a decrease in cell permeability. The higher hydrophilicity of 68Ga-NODAGA-Erlotinib also led to significantly lower accumulation of 68Ga-NODAGA-Erlotinib in non-target organs in the biodistribution studies in Swiss mice. The overall properties of the 68Ga-NODAGA-Erlotinib conjugate are promising and reflect the role of hydrophilicity in reducing the non-specific uptake of the final radiotracer towards improving signal/noise ratio for further imaging studies.

    Source:: http://www.pubs.iscience.in/journal/index.php/cbl/article/view/727

          

  • Dr Brijesh Rathi

    Dr. Brijesh Rathi,
    Department of Chemistry,
    Hansraj College,
    University of Delhi,
    Delhi-110007. India

    webpage: http://hansrajcollege.ac.in/faculty-info.php?id=28

    Research Interests: Medicinal Chemistry, Maleria, Drug development, synthetic organic chemistry, peptide chemistry, peptide drugs, nanomedicine.

    Dr. Brijesh Rathi is a faculty of Chemistry in Hansraj College, University of Delhi and associated with Chemical Biology Letters and Applied NanoMedicine as Editorial Board Member.

  • Prof. Carmela Saturnino

    Carmela Saturnino
    Prof. in Medicinal Chemistry
    Department of Science
    University of Basilicata
    viale dell’Ateneo Lucano
    Potenza
    ITALY

    Research Interest: Medicinal Chemistry

    Prof. Saturnino is Professor of Medicinal Chemistry in University of Basilicata, Italy and associated with Chemical Biology Letters ( http://pubs.iscience.in/journal/index.php/cbl/pages/view/editorialboard ) as Editorial Advisory Board Member.